SELLAS Life Sciences
24 hedge funds and large institutions have $1.99M invested in SELLAS Life Sciences in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 7 closing their positions.
4,530% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $23K
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
14% less funds holding
Funds holding: 28 → 24 (-4)
26% less capital invested
Capital invested by funds: $2.68M → $1.99M (-$690K)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$126K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.6K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$12.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$77.8K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$25.1K |
| 3 |
Millennium Management
New York
|
-$24K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$18K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$16K |
SLS Hedge Fund Activity: Q4 2017 in Review
24 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q4 2017, worth a combined $1.99M — down 26% from $2.68M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SLS and 3 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $126K. The largest seller was Vanguard Group, cutting an estimated $77.8K.
- 24 institutional investors held SELLAS Life Sciences (SLS) as of Q4 2017, down from 28 in Q3 2017.
- Funds reported $1.99M of SELLAS Life Sciences stock for Q4 2017, down 26% quarter-over-quarter.
- 3 funds opened new SELLAS Life Sciences positions in Q4 2017 and 7 closed out, a net change of -4 holders.
- The largest SELLAS Life Sciences buyer in Q4 2017 was Renaissance Technologies, an estimated $126K added.
- The largest SELLAS Life Sciences seller in Q4 2017 was Vanguard Group, an estimated $77.8K sold.
Based on aggregated 13F filings for Q4 2017.